The dominant role of G12C over other KRAS mutation types in the negative prediction of efficacy of epidermal growth factor receptor tyrosine kinase inhibitors in non …
O Fiala, M Pesek, J Finek, L Benesova, B Belsanova… - Cancer genetics, 2013 - Elsevier
The role of KRAS mutations in molecular targeted therapy by epidermal growth factor receptor
tyrosine kinase inhibitors (EGFR-TKIs) in non–small cell lung cancer (NSCLC) has not …
tyrosine kinase inhibitors (EGFR-TKIs) in non–small cell lung cancer (NSCLC) has not …
[PDF][PDF] Cancer epidemiology in Central and South Eastern European countries
…, T Pienkowski, G Bodoky, P Berzinec, J Finek… - Croatian medical …, 2011 - hrcak.srce.hr
… Eduard Vrdoljak1, Marek Z Wojtukiewicz2, Tadeusz Pienkowski3, Gyorgy Bodoky4, Peter
Berzinec5, Jindrich Finek6, Vladimir Todorović7, Nenad Borojević8, Adina Croitoru9, for …
Berzinec5, Jindrich Finek6, Vladimir Todorović7, Nenad Borojević8, Adina Croitoru9, for …
G12V and G12A KRAS mutations are associated with poor outcome in patients with metastatic colorectal cancer treated with bevacizumab
…, V Liska, O Topolcan, M Sedivcova, J Finek - Tumor Biology, 2016 - Springer
The v-Ki-ras2 Kirsten rat sarcoma viral oncogene homolog (KRAS) mutations are found in
35–45 % of colorectal cancer (CRC) cases. Although the association between the RAS …
35–45 % of colorectal cancer (CRC) cases. Although the association between the RAS …
Oral vinorelbine in metastatic breast cancer: a review of current clinical trial results
M Aapro, J Finek - Cancer treatment reviews, 2012 - Elsevier
BACKGROUND: Oral chemotherapy is one of the options for the treatment of endocrine non-responsive
metastatic breast cancer. PATIENTS AND METHODS: A search of the online …
metastatic breast cancer. PATIENTS AND METHODS: A search of the online …
Predictive role of CEA and CYFRA 21-1 in patients with advanced-stage NSCLC treated with erlotinib
O Fiala, M Pesek, J Finek, L Benesova… - Anticancer …, 2014 - ar.iiarjournals.org
Background: Tumor biomarkers are used for predicting therapy effect and prognosis of patients
with non-small cell lung cancer (NSCLC). We focused on their potential role in prediction …
with non-small cell lung cancer (NSCLC). We focused on their potential role in prediction …
Immune-related adverse effects and outcome of patients with cancer treated with immune checkpoint inhibitors
…, JAN Sustr, R Kucera, O Topolcan, J Finek - Anticancer …, 2020 - ar.iiarjournals.org
Immunotherapy based on immune checkpoint inhibitors (ICIs) represents a novel anticancer
treatment strategy. Monoclonal antibodies targeting cytotoxic T-lymphocyte antigen-4 (…
treatment strategy. Monoclonal antibodies targeting cytotoxic T-lymphocyte antigen-4 (…
18F-FDG-PET/CT in potentially advanced renal cell carcinoma: a role in treatment decisions and prognosis estimation
J Ferda, E Ferdova, M Hora, O Hes, J Finek… - Anticancer …, 2013 - ar.iiarjournals.org
Aim: to assess the influence of positron emission tomography/computed tomography with
18 F-fluorodeoxyglucose ( 18 F-FDG-PET/CT) on the treatment decision in renal cell …
18 F-fluorodeoxyglucose ( 18 F-FDG-PET/CT) on the treatment decision in renal cell …
MIC1/GDF15 as a bone metastatic disease biomarker
…, R Kucera, O Topolcan, O Fiala, J Finek… - Anticancer …, 2017 - ar.iiarjournals.org
Aim: The aim of the study was to evaluate MIC1/GDF15 as a biomarker in the monitoring of
bone metastases occurrence. Patients and Methods: The assessed group included patients …
bone metastases occurrence. Patients and Methods: The assessed group included patients …
A phase II trial of oral vinorelbine and capecitabine in anthracycline pretreated patients with metastatic breast cancer
J Finek, L HOLUBEC, T Svoboda… - Anticancer …, 2009 - ar.iiarjournals.org
Background: Optimal chemotherapy (CT) for advanced breast treatment should be effective,
well tolerated and convenient. In this study the efficacy and safety of the fully oral …
well tolerated and convenient. In this study the efficacy and safety of the fully oral …
[HTML][HTML] Health resource utilization associated with skeletal-related events: results from a retrospective European study
…, N Maniadakis, E Terpos, YP Acklin, J Finek… - The European Journal of …, 2016 - Springer
Background Bone complications, also known as skeletal-related events (SREs), are common
in patients with bone metastases secondary to advanced cancers. Objective To provide a …
in patients with bone metastases secondary to advanced cancers. Objective To provide a …